www.QualityStocks.Net would like to highlight Rexahn Pharmaceuticals, Inc. (AMEX: RNN). The company is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn’s compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain their quality of life.
In the company’s recent news,
Rexahn Pharmaceuticals, Inc. (AMEX: RNN) announced that the company has received FDA approval to begin Phase II trials for Serdaxin™, for the treatment of major depressive disorders. Serdaxin is being developed as an orally administered, extended-release tablet for the treatment of depression and anxiety.
According to the World Health Organization, major depressive disorder is the leading cause of disability in the United States for ages 15 to 44. There are 154 million cases of depression reported worldwide each year, and this condition is nearly twice as prevalent in women as in men. Major depressive disorder is expected to become the second-leading cause of disability worldwide by the year 2020.
Serdaxin is a dual enhancer of serotonin and dopamine neurotransmitters. In preclinical studies, Serdaxin was shown to significantly improve an individual’s negative mood state and the loss of positive mood state, with the onset of action taking less than 48 hours. Serdaxin has shown no serious side effects, cognitive deficit or motor impairment. The Serdaxin Phase II trial is a randomized, double-blind, placebo-controlled parallel study for the treatment of major depressive disorders (MDD). It is a multi-center trial with preliminary data in humans expected in the second half of 2009.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
